Systematic Review on Efficacy and Safety of Ribavirin in the Treatment of Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome

WU Ziyang; DU Xin; CHEN Ken; CHENG Yinchu; WANG Zhiyan; ZHAI Suodi; LIU Wei; XIE Xiaohui

doi:10.14009/j.issn.1672-2124.2020.10.021

您当前的位置：

首页 >

文章列表页 >

Systematic Review on Efficacy and Safety of Ribavirin in the Treatment of Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome

更新时间：2022-10-08

- Systematic Review on Efficacy and Safety of Ribavirin in the Treatment of Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome
- Vol. 20, Issue 10, Pages: 1236-1239(2020)
- 作者机构：
  
  1. 北京大学药学院药事管理与临床药学系
  2. 北京大学第三医院药剂科
  3. 美国内布拉斯加大学医学中心药学院
  4. 赤峰市肿瘤医院药剂科
  5. 北京大学医学部药物评价中心
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.10.021
  CLC： R563
- Published：2020，
扫描看全文
[1]吴紫阳,杜欣,陈恳,程吟楚,王志妍,翟所迪,刘维,谢晓慧.利巴韦林治疗严重急性呼吸综合征和中东呼吸综合征的有效性与安全性的系统综述[J].中国医院用药评价与分析,2020,20(10):1236-1239.

WU Ziyang, DU Xin, CHEN Ken, et al. Systematic Review on Efficacy and Safety of Ribavirin in the Treatment of Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. [J]. 20(10):1236-1239(2020)
[1]吴紫阳,杜欣,陈恳,程吟楚,王志妍,翟所迪,刘维,谢晓慧.利巴韦林治疗严重急性呼吸综合征和中东呼吸综合征的有效性与安全性的系统综述[J].中国医院用药评价与分析,2020,20(10):1236-1239. DOI： 10.14009/j.issn.1672-2124.2020.10.021.

WU Ziyang, DU Xin, CHEN Ken, et al. Systematic Review on Efficacy and Safety of Ribavirin in the Treatment of Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. [J]. 20(10):1236-1239(2020) DOI： 10.14009/j.issn.1672-2124.2020.10.021.

摘要

目的:基于严重急性呼吸综合征（severe acute respiratory syndrome

SARS）和中东呼吸综合征（Middle East respiratory syndrome

MERS）中利巴韦林的使用进行系统综述

为利巴韦林用于新型冠状病毒肺炎（COVID-19）提供循证医学依据。方法:系统检索Pub Med、EMBase等中英文数据库

对所纳入的文献进行质量评价、数据提取

并对疗效、不良反应和用药方案加以分析。结果:经检索共获得3 415篇文献

最终纳入77项研究。分析结果显示

利巴韦林治疗SARS、MERS的疗效并未取得一致性结论

且剂量相关的贫血发生率高。结论:根据本文分析

在我国《新型冠状病毒肺炎诊疗方案（试行第七版）》推荐的基础上

建议利巴韦林应在疾病进程早期使用。此外

使用利巴韦林治疗COVID-19的有效性与安全性

仍需在临床应用中进一步研究。

Abstract

OBJECTIVE: To conduct a systematic review on the application of ribavirin in the treatment of severe acute respiratory syndrome（ SARS） and Middle East respiratory syndrome（ MERS）

so as to provide evidence-based evidence for ribavirin in the treatment of COVID-19. METHODS: Chinese and foreign database including Pub Med and EMBase were retrieved

involved studies were conducted quality evaluation and data extraction

efficacy

adverse drug reactions and therapeutic regimen were analyzed. RESULTS: Totally 3 415 papers were retrieved

finally 77 studies were enrolled. Analysis results showed that the efficacy of ribavirin in the treatment of SARS and MERS had not reached a consistent conclusion

and the incidence of dose-related anemia was high. CONCLUSIONS: According to the analysis of this article

based on the recommendations of "COVID-19 Diagnosis and Treatment Scheme（ Trialed Seventh Edition） "

it is recommended that ribavirin should be used in the early stage of disease progress. In addition

the effectiveness and safety of ribavirin in the treatment of COVID-19 still need further study in clinical applications.

关键词

利巴韦林严重急性呼吸综合征中东呼吸综合征新型冠状病毒肺炎

Keywords

RibavirinSevere acute respiratory syndromeMiddle East respiratory syndromeCOVID-19

references

查看原文

Views

108

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Reasonable Application of Antiviral Drugs in the Treatment of COVID-19

Progress of Antiviral Research of Arbidol

Systematic Review of Efficacy and Safety of Lopinavir/Ritonavir in Patients with COVID-19

Application of Traditional Chinese Medicine Injection in the Treatment of COVID-19

Mechanism of Ganlu Xiaodu Decoction on COVID-19 Treatment Based on Network Pharmacology

Related Author

XU Xiaohan

ZHAI Suodi

YANG Li

BAI Jiawei

MA Chengtai

WEI Jie

WU Miao

DU Xianjin

Related Institution

Dept.of Emergency, Renmin Hospital of Wuhan University

Dept.of Critical Care Medicine, Renmin Hospital of Wuhan University

Dept.of Pharmacy,Xiamen Children’s Hospital

Dept.of Pharmacy,Guang’anmen Hospital of China Academy of Chinese Medical Sciences

Dept. of Pharmacy, China-Japan Friendship Hospital

⁰